Please wait while the formulary information is being retrieved.
METOCLOPRAMIDE HCL (METOCLOPRAMIDE HCL)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Diabetic gastroparesis
- Gastrointestinal radiography adjunct
- Intubation of gastrointestinal tract
metoclopramide 5 mg/mL injection syringe
- Dosage information is not available
metoclopramide 5 mg/mL injection syringe
- Dosage information is not available
Cancer chemotherapy-induced nausea and vomiting
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route once
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 4 hours as needed
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 6 hours as needed
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 4-6 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route once
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 4 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 6 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 4-6 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route once
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 4 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 6 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 4-6 hours as needed
Gastrointestinal radiography adjunct
- Infuse 2 milliliters (10 mg) by intravenous route x1 dose
Intubation of gastrointestinal tract
- Infuse 2 milliliters (10 mg) by intravenous route x1 dose
Prevention of chemotherapy-induced nausea and vomiting
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route once
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 4 hours as needed
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 6 hours as needed
- Inject 2 milliliters (10 mg) over 1-2 minute(s) by intravenous route every 4-6 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route once
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 4 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 6 hours as needed
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route every 4-6 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route once
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 4 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 6 hours as needed
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route every 4-6 hours as needed
Prevention of post-operative nausea and vomiting
- Infuse 4 milliliters (20 mg) over 15-30 minute(s) by intravenous route once
- Infuse 5 milliliters (25 mg) over 15-30 minute(s) by intravenous route once
- Infuse 8 milliliters (40 mg) over 15-30 minute(s) by intravenous route once
- Infuse 10 milliliters (50 mg) over 15-30 minute(s) by intravenous route once
- Abilify
- Abilify Discmelt
- Abilify Maintena
- Adasuve
- aripiprazole
- asenapine
- cabergoline
- chlorpromazine
- clozapine
- Clozaril
- Compazine
- Compro
- droperidol
- Fazaclo
- fluphenazine decanoate
- fluphenazine HCl
- Geodon
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Invega
- Invega Sustenna
- Latuda
- loxapine
- loxapine succinate
- Loxitane
- lurasidone
- olanzapine
- olanzapine pamoate
- olanzapine-fluoxetine
- Orap
- paliperidone
- paliperidone palmitate
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- pimozide
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- quetiapine
- Risperdal
- Risperdal Consta
- Risperdal M-tab
- risperidone
- risperidone microspheres
- Saphris
- Saphris (black Cherry)
- Seroquel
- Seroquel Xr
- Symbyax
- thioridazine
- thiothixene
- trifluoperazine
- Versacloz
- ziprasidone HCl
- ziprasidone mesylate
- Zyprexa
- Zyprexa Relprevv
- Zyprexa Zydis
Contraindicated
- atovaquone
- atovaquone-proguanil
- Azilect
- Brisdelle
- Celexa
- citalopram
- Cymbalta
- desvenlafaxine
- desvenlafaxine fumarate
- desvenlafaxine succinate
- duloxetine
- Effexor Xr
- Eldepryl
- escitalopram oxalate
- Fetzima
- fluoxetine
- fluvoxamine
- isocarboxazid
- Khedezla
- levomilnacipran
- Lexapro
- linezolid
- Luvox Cr
- Malarone
- Malarone Pediatric
- Marplan
- Matulane
- Mepron
- methylene blue (antidote)
- milnacipran
- Nardil
- Parnate
- paroxetine HCl
- paroxetine mesylate
- Paxil
- Paxil Cr
- Pexeva
- phenelzine
- Pristiq
- procarbazine
- Prozac
- Prozac Weekly
- rasagiline
- Sarafem
- Savella
- selegiline HCl
- sertraline
- tranylcypromine
- venlafaxine
- Viibryd
- vilazodone
- Zelapar
- Zoloft
- Zyvox
Severe
Moderate
- Anectine
- cyclosporine
- cyclosporine modified
- Digox
- digoxin
- Gengraf
- Lanoxin
- Neoral
- Quelicin
- Sandimmune
- succinylcholine chloride
- Acquired dystonia
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Mechanical intestinal obstruction
- Neuroleptic malignant syndrome
- Pheochromocytoma
- Seizure disorder
- Tardive dyskinesia
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- CYp2d6 poor metabolizer
- Depression
- Disease of liver
- NADH methemoglobin reductase deficiency
- Parkinsonism
- Porphyria
- Suicidal ideation
Severe
Moderate
- Aldosteronism
- Chronic heart failure
- Edema
- Hepatic cirrhosis
- Hyperprolactinemia
- Hypertension
- Intestinal anastomosis
METOCLOPRAMIDE HCL (METOCLOPRAMIDE HCL)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Diabetic gastroparesis
- Gastrointestinal radiography adjunct
- Intubation of gastrointestinal tract
- None
- Diarrhea
- Drowsy
- Fatigue
- Nervousness
More Frequent
Severe
Less Severe
- None
- Dizziness
- Gynecomastia
- Headache disorder
- Mastalgia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acquired dystonia
- Agitation
- Agranulocytosis
- Akathisia
- Angioedema
- Atrioventricular block
- Bradycardia
- Bronchospastic pulmonary disease
- Chronic heart failure
- Extrapyramidal disease
- Hypertension
- Hypotension
- Jaundice
- Laryngeal edema
- Leukopenia
- Methemoglobinemia
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Panic disorder
- Parkinsonism
- Porphyria
- Seizure disorder
- Suicidal
- Suicidal ideation
- Supraventricular tachycardia
- Tachycardia
- Tardive dyskinesia
Less Severe
- Acute confusion
- Amenorrhea
- Body fluid retention
- Depression
- Erectile dysfunction
- Galactorrhea not associated with childbirth
- Hyperprolactinemia
- Increased urinary frequency
- Insomnia
- Irregular menstrual periods
- Irritability
- Nausea
- Skin rash
- Urinary incontinence
- Urticaria
- Visual changes
Contraindicated
Metoclopramide
Extrapyramidal effects more likely to occur in children age < 1 year. Rare risk of tardive dyskinesia with prolonged administration. Risk of methemoglobinemia in neonates.
- 1 Day – 364 Days
- 1 Extrapyramidal effects more likely to occur in children age < 1 year. Rare risk of tardive dyskinesia with prolonged administration. Risk of methemoglobinemia in neonates.
Severe Precaution
Metoclopramide
Increased risk of extrapyramidal symptoms, dystonia. Rare risk of tardive dyskinesia with prolonged administration. Not recommended per manufacturer.
- 1 Years – 18 Years
- Increased risk of extrapyramidal symptoms, dystonia. Rare risk of tardive dyskinesia with prolonged administration. Not recommended per manufacturer.
Management or Monitoring Precaution
None
Metoclopramide
- Severity Level:
2
- Additional Notes: May cause ep signs & methemoglobinemia in neonates exposed during birth
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Metoclopramide
Monitor nursing infant for eps and methemoglobinemia
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Drug shown to have adverse effect | Monitor nursing infant for eps and methemoglobinemia |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Metoclopramide
General-Avoid high doses and long duration of use. AVOID treatment for longer than 12 weeks. Neuro/Psych-Neurological and psychiatric adverse effects including depression/suicidal ideation and greater risk of tardive dyskinesia. Risk of parkinsonian-like reactions increases with ascending doses; discontinue use if they occur. Sedation is more common in elderly and contributes to increased confusion and falls. Renal- Reduce dose for CrCL < 61mL/min and monitor renal function.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | Y | N | Y |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- This medication may cause a serious movement disorder called tardive dyskinesia. In some cases, this condition may be permanent. The risk of tardive dyskinesia is increased with the longer use of the medication and the more medication that you receive.<br /><br />The risk is also increased in older adults (especially women) and in people with diabetes. Do not use metoclopramide for longer than 12 weeks. Talk to your doctor about the risks and benefits of this medication.<br /><br /> Tell your doctor right away if you develop any unusual uncontrolled movements (especially of the face, mouth, tongue, arms or legs). There is no treatment for tardive dyskinesia, but in some cases the symptoms may lessen or stop once metoclopramide is stopped.
| Diabetic gastroparesis | |
| E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
| E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
| E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
| K31.84 | Gastroparesis |
| 0-9 | A-Z |
|---|---|
| E08.43 | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
| E09.43 | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
| E10.43 | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E11.43 | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E13.43 | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
| K31.84 | Gastroparesis |
Formulary Reference Tool